By proceeding, you agree to our Terms of Use and Privacy Policy.
The Biomarker and Companion Diagnostics Conference, organized by MarketsandMarkets, is set to take place on the 22nd and 23rd of June 2023 in Boston, USA. The event aims to explore how next-generation technologies can be used to advance biomarker drug discovery beyond conventional methods.The conference will feature presentations by over 30 experts from academia and industry, who will share their current research in the areas of biomarkers, regulatory guidelines, cancer biomarker validation, personalized medicine, big data in translational biomarker research, and the future of companion diagnostics.Attendees will have the opportunity to develop lasting business relationships and network with professionals from pharmaceutical and bio-pharma companies, universities, research institutes, clinicians, and scientists.The event will consist of more than 20 presentations, round-tables, and panel discussions, which will focus on the major opportunities and challenges in biomarker research. These discussions will cover various topics, such as precision medicine, companion diagnostics, digital biomarkers, and clinical trials.
Explore the world of personalized medicine through keynote sessions, case studies, and technical workshops.
Learn from the examples and the case studies which will help in creating the revenue. The keynote presentations would also help you understand the issues related to clinical translation of biomarkers.
Partake in presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.
Get inspired by 30+ experts from academia and industry who will be presenting their current work in biomarkers, impact of big data in translational biomarker research and future of companion diagnostics.
In the decade of the 2020s, the B2B world will see $25 trillion worth of disruptive revenue shifts. Organizations globally are navigating both the opportunities and risks that are consequent.
Danaher is a global science and technology innovator committed to helping our customers solve complex challenges and improve quality of life around the world.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Burning Rock's laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.